Skip to content
Advertisement
Isomorphic Labs raises $5 billion in Series C to push AI-designed drugs toward clinical trials

Isomorphic Labs raises $5 billion in Series C to push AI-designed drugs toward clinical trials

The Google DeepMind spinout's latest round, co-led by Greenoaks and Sequoia Capital, lifts its external funding since March 2025 to about $7.7 billion

Isomorphic Labs has raised $5 billion in a Series C round, one of the largest private checks ever written to a company that has yet to put a drug into human trials.

The AI drug discovery firm, spun out of Google DeepMind in 2021, plans to use the cash to move its first drug candidates into clinical trials.

The details of the round

The Series C was announced on November 17, 2026, and co-led by Greenoaks and Sequoia Capital.

Andreessen Horowitz joined as a new investor. Every existing backer also came back for more, including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.

The company did not share its valuation. Earlier reporting had put Isomorphic at roughly $50 billion, though the firm has not confirmed a figure tied to this round.

Advertisement

Isomorphic closed a $2.1 billion Series B led by Thrive Capital in May 2026, roughly six months before this round. Before that, it raised approximately $600 million in March 2025. Add it up and total external funding since March 2025 now stands at about $7.7 billion.

Where the money is going

Isomorphic is led by CEO Sir Demis Hassabis. The company says the new capital will go toward three main areas.

First is its proprietary drug design engine, called IsoDDE. Second is its pipeline of therapeutic candidates. The company has reported positive preclinical results in oncology and immunology. Third is infrastructure for AI-led bioengineering.

The scientific foundation traces back to DeepMind. Isomorphic builds on technology like AlphaFold, the system that predicts the 3D shapes of proteins from their amino acid sequences.

The pharma partnerships

Isomorphic has partnerships with Eli Lilly, Novartis and Johnson & Johnson.

Background: from protein folding to drug pipelines

Isomorphic was created in 2021 to take DeepMind’s research and turn it into actual medicines. The company’s latest moves show it is shifting from platform story to pipeline story. Preclinical results in oncology and immunology are encouraging, but preclinical success has a long history of not translating cleanly into human outcomes.

What this means

The investor list includes Sequoia, Greenoaks and Andreessen Horowitz alongside sovereign and state-linked money like Temasek, MGX and the UK Sovereign AI Fund.

The key risk is timing. Valuations built on preclinical promise can wobble quickly when trial data arrives, and clinical development operates on timelines measured in years, not funding cycles.

The main thing to watch now is the transition into the clinic. The first human trials will be the moment Isomorphic’s approach gets tested against the one benchmark that money cannot buy: whether the drugs actually work in patients.

Disclosure: This article was edited by Diego Almada Lopez. For more information on how we create and review content, see our Editorial Policy.